Case report: Management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir

Journal of Medical Virology

Volumn 84, Issue 9, 2012, Pages 1340-1343

  Mikulska, Malgorzata ^a   Taramasso, Lucia ^a   Giacobbe, Daniele Roberto ^a   Caligiuri, Patrizia ^b   Bruzzone, Bianca ^a   Di Biagio, Antonio ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Entecavir; R192PR mutation; Resistance; TDF resistance

Indexed keywords

DARUNAVIR; EMTRICITABINE; ENFUVIRTIDE; ENTECAVIR; LAMIVUDINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; DRUG TREATMENT FAILURE; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; PATIENT COMPLIANCE; VIRUS GENE; VIRUS LOAD;

ADENINE; ANTI-HIV AGENTS; COINFECTION; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; ORGANOPHOSPHONATES; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84864133981     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23338     Document Type: Article

References (16)

1. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. 2009. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 49: 1158-1165.
2. Audsley J, Arrifin N, Yuen LK, Ayres A, Crowe SM, Bartholomeusz A, Locarnini SA, Mijch A, Lewin SR, Sasadeusz J. 2009. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med 10: 229-235.
3. Baraclude (entecavir). 2010. Prescribing information. Bristol-Myers Squibb Company. Princeton, NJ, USA.
4. Bodsworth N, Donovan B, Nightingale BN. 1989. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: A study of 150 homosexual men. J Infect Dis 160: 577-582.
5. Delaney WET, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. 2006. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 50: 2471-2477.
6. DHHS. 2011. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human services. Updated 14 October 2011. Accessed 1 December 2011. Available from
7. EASL. 2009. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 50: 227-2242.
8. Fournier C, Zoulim F. 2007. Antiviral therapy of chronic hepatitis B: Prevention of drug resistance. Clin Liver Dis 11: 869-892, ix.
9. Locarnini S. 2008. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2: 147-151.
10. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. 2007. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 46: 254-265.
11. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442-2455.
12. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. 2011. Managing hepatitis B/HIV co-infected: Adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 25: 1051-1056.
13. Shaw T, Bartholomeusz A, Locarnini S. 2006. HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol 44: 593-606.
14. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, Nunez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. 2005. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10: 727-734.
15. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F. 2008. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48: 747-755.
16. Williamson MP. 1994. The structure and function of proline-rich regions in proteins. Biochem J 297: 249-260.